XTend Medical acquires rights to DDI’s vibration device

Paul Lisenby, CEO of XTend Medical, said: “Once the FDA has cleared the device for sale, we will immediately begin marketing the product to our managed care companies and the various physicians and patients here in the US. We’re also in negotiations to market the product in South Korea and Europe based on their separate criteria needs for final approval.

“Once these are received, then we’ll target these markets heavily. Although the device can pre-screen people that may have diabetic neuropathy, the first signs that diabetes may be present, it also assists the current diabetic patient with monitoring their neuropathy levels so their disease is managed correctly.”